PDGFRB and uterine cervix neoplasm: To further characterize the potential participation of PDGFR in cervical cancer development and to determine the presence of gene-activating mutations or mutations associated to imatinib resistance, we performed a mutational analysis of the PDGFRα exons 12 and 18 in the DNA extracted from the 8 cell lines and the frozen cervical tumors.